Purpose To assess the significance of CA-125 regression as a prognostic indicator and predictor of optimal cytoreduction at interval debulking surgery (IDS) in women with ovarian or primary peritoneal carcinoma receiving neoadjuvant chemotherapy (NAC). Methods 63 women treated between 2004 and 2007 with neoadjuvant platinum-based chemotherapy followed by IDS were studied retrospectively. Pre-operative CA-125 values were used to calculate a regression coefficient (CA-125r) using exponential regression analysis. Outcome endpoints were overall survival (OS), time to CA-125 progression (TTC) by Rustin criteria and time to secondline treatment (TTS). Results Women with a CA-125 half-life greater than 18 days had a significantly worse OS compared to those with a half-life less than 12 days on univariate testing (HR 3.34,, p = 0.017). On multivariable analysis, CA-125r was an independent predictor of OS [HR 1.18 (per 0.01 increase in CA-125r), 95% CI 1.01-1.40, p = 0.043]. CA-125r was independently predictive of TTC and TTS (HR 1.17, p & 0.03 for each). CA-125r was also predictive of achieving optimal cytoreduction at IDS (AUC 0.756, p \ 0.001).
Introduction
The conventional treatment of advanced ovarian and primary peritoneal carcinoma is initial cytoreductive surgery followed by chemotherapy. In recent years, an alternative treatment approach of platinum-based chemotherapy followed by interval debulking surgery (IDS) has increasingly been adopted, particularly in high-risk surgical candidates and/or patients where optimal primary cytoreduction is felt unlikely to be possible. Whether such an approach is suitable for all women with stage III and IV diseases remains controversial [1, 2] . The recently presented results of the EORTC-GCG phase III randomized study suggest that neoadjuvant chemotherapy (NAC) achieves higher rates of optimal cytoreduction, with reduced morbidity, for equivalent survival in comparison to up-front surgery [3] . The results of two further randomized phase III trials (MRC CHORUS and JCOG0206) are awaited.
A potential advantage of the NAC approach is that it can provide the treating clinician with early information regarding the chemosensitivity of the tumor using clinical, radiological and tumor marker criteria. Decreasing CA-125 levels are known to correlate with response to chemotherapy [4] . In the post-operative setting, absolute CA-125 levels and CA-125 regression are known to be prognostic of outcome [5, 6] . In the neoadjuvant setting, where the effect of surgery is excluded, the value of CA-125 remains unclear. The ability to predict optimal cytoreduction, a factor strongly associated with improved outcome [7] , is desirable. Recent studies examining absolute CA-125 levels pre-operatively have reported conflicting results [8, 9] . The value of CA-125 regression during NAC as a predictor of optimal cytoreduction at IDS has not been explored.
In the current study, we have examined whether CA-125 regression during NAC predicts for optimal cytoreduction and correlates with outcome in women with newly diagnosed ovarian or primary peritoneal cancer.
Patients and methods

Patients
We conducted a retrospective study of women diagnosed with advanced ovarian or primary peritoneal carcinoma, treated in our institution with neoadjuvant platinum-based chemotherapy followed by IDS between 2004 and 2007. Standard IDS consisted of total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and paraaortic and pelvic lymph node dissection. We included women with FIGO stage III or IV disease as defined by baseline CT imaging, biopsy and/or cytology. Women who had initial laparotomy with minimal, or no debulking (e.g. for bowel obstruction, acute abdomen, omentectomy only, or ''open and close'' laparotomy) were included provided they subsequently had chemotherapy followed by IDS. Patients with germ-cell, purely stromal or borderline histology, tumors of unknown primary and women with synchronous malignancies were excluded.
Statistical analysis SPSS (version 15; Chicago, IL, USA) and R (R Development Core Team, Vienna, Austria) software packages were used for statistical analysis. Estimate of the survival function was computed using the Kaplan-Meier method. Cox's proportional hazards regression [10] was used to evaluate univariate and independent multivariable associations with the effect of clinical, pathological and CA-125 kinetic parameters on outcome endpoints. Age, site of primary, morphology, grade, FIGO stage, the presence of ascites, degree of cytoreduction as defined by the surgeon (B or [1 cm residual disease), chemotherapy regimen and pre-operative CA-125 regression coefficient (CA-125r) (continuous variable and as tertiles) were considered for all patients. The multivariable model included age, stage, grade, degree of cytoreduction, and CA-125r (continuous variable only). Receiver operator characteristic (ROC) curve analysis was performed to evaluate CA-125r as a predictor of optimal cytoreduction. Independent predictive ability of optimal cytoreduction using CA-125r was evaluated using multiple logistic regression.
Outcome endpoints were defined as follows-overall survival (OS): interval between date of first chemotherapy cycle and death, or last follow up; time to CA-125 progression (TTC): interval between date of first chemotherapy cycle and date of CA-125 progression from nadir value, as per Gynecologic Cancer Intergroup (GCIG) criteria [11] , or date of death, or last follow up; time to second-line treatment (TTS): interval between date of first chemotherapy cycle and date of commencing second line, or rechallenge, treatment (chemotherapy, tamoxifen, radiotherapy, surgery), or date of decision for best supportive care only, or date of death, or last follow up.
CA-125 regression coefficients
Serum CA-125 levels measured from time of diagnosis until death or last follow up were recorded. The assay was performed by the Clinical Biochemistry Department, St. James's University Hospital, Leeds, using an Advia Centaur sandwich immunoassay (Siemens, Camberley, UK). Regression coefficients (CA-125r) were calculated with exponential regression analysis in SPSS using all the CA-125 levels from time of starting NAC (including up to 5 days before the start of chemotherapy) until CA-125 normalization or day of IDS. Example regression curves for patients with a high, average and low CA-125 regression coefficients are shown in Fig. 1 .
Results
In total, 63 women fulfilling the above criteria were identified. Their characteristics are presented in Table 1 . The median length of follow up from commencing NAC was 31.8 months (range 4.9-55.1 months).
In each case, the decision to adopt a neoadjuvant treatment approach was made at a Multidisciplinary Team (MDT) meeting. Overall (Table 1 ), 14 (22%) women were considered unfit for primary surgery (in terms of surgical risk). 8 (13%) of the 63 patients had initial laparotomy with little or no tumor debulking. Seventeen (27%) women received single agent carboplatin in both the neoadjuvant and post-operative phases. Five (8%) women received carboplatin pre-operatively which was changed to a taxane containing regimen postoperatively: 3 paclitaxel and gemcitabine; 1 paclitaxel and carboplatin; 1 docetaxel and carboplatin. 41 (65%) women commenced neoadjuvant combination carboplatin and paclitaxel chemotherapy. Of these 41 patients, 1 required a change to single agent carboplatin pre-operatively and 5 post-operatively due to paclitaxel-related toxicity.
The number of cycles of chemotherapy patients received pre-operatively is shown in Table 1 . Overall (pre-and post-operative chemotherapy combined), 51 (81%) women received six cycles of chemotherapy, 1 (2%) four cycles, 3 (4%) five cycles, 2 (3%) seven cycles, 5 (8%) eight cycles and 1 (2%) nine cycles.
Normalization of CA-125 (\35 IU/ml) prior to IDS and on completion of post-surgical chemotherapy was observed in 15 (24%) and 49 (78%) of patients, respectively. In the pre-operative phase, 60 women had between two and seven CA-125 measurements (median 3). Three women had only one pre-operative CA-125 measurement and were excluded from tumor marker kinetics analysis.
The CA-125 pre-operative regression coefficient CA-125r ranged from -0.119 (max regression) (corresponding to a CA-125 half-life of 5.82 days) to -0.01 (corresponding to a CA-125 half-life of 69.3 days). One patient had a positive CA-125r (0.001) and essentially static CA-125 (Table 2) . Twenty-one women (33.3%) underwent paracentesis during, or within 14 days of starting, NAC.
Univariate analysis
On univariate analysis, factors significantly (p \ 0.05) associated with OS, TTS and TTC were degree of cytoreduction at IDS and CA-125r, when considered both in tertiles and as a continuous variable (Table 3) .
Multivariable analysis
When considering all variables within the multivariable model for OS, no factors were independently prognostic. However, when degree of cytoreduction was removed from the model (since it is an unknown variable prior to surgery), CA-125r was the only factor predictive of OS [HR Table 4 ]. In other words, when considering the extremes of CA-125r within our population, the hazard of death for a woman with a CA-125r of -0.01 was 12.98 times that of a woman with a CA-125r of -0.119. Kaplan-Meier curves for OS based on CA-125r considered as tertiles (low, medium and high) are shown in Fig. 2a . Women in the lowest tertile had a CA-125 half-life of less than 11.8 days, the medium tertile had a CA-125 half-life of between 11.8 and 17.9 days and the highest tertile had a half-life of greater than 17.9 days. Median OS at 3 years in patients with low, medium and high CA-125r (equivalent to short, average and long CA-125 half-life) was 52.7, 21.8 and 24.8 months, respectively.
When TTS was examined, considering all variables including degree of cytoreduction, CA-125r was the only variable with independent prognostic value [HR 1.17 (per 0.01 increase in CA-125r), 95% CI 1.02-1.35, p = 0.025]. Similarly, CA-125r was the only variable with independent prognostic value for TTC [HR 1.17 (per 0.01 increase in CA-125r), 95% CI 1.02-1.34, p = 0.032]. KaplanMeier curves for TTS and TTC based on CA-125r considered as tertiles (low, medium and high) are shown in Fig. 2b and c.
Ability of CA-125r to predict optimal cytoreduction ROC curve analysis demonstrated that CA-125r was strongly predictive of optimal cytoreduction [area under the curve (AUC) 0.756; p \ 0.001, not shown]. CA-125r was also found to be independently predictive of optimal cytoreduction in a multiple logistic regression model (p = 0.003) also containing age, stage and grade.
Discussion
Despite the fact that conclusive randomized data are still awaited, NAC followed by IDS is increasingly used in the management of women with advanced ovarian or primary peritoneal carcinoma. Pre-operative chemotherapy may reduce subsequent surgical risk and/or allow maximal cytoreductive surgery, provided an adequate response to treatment is achieved. The assessment of response to NAC is thus important and, in parallel with other malignancies (e.g. breast cancer), such knowledge may allow early detection of chemoresistance and appropriate tailoring of chemotherapy regimen. This may maximize the chance of achieving macroscopic clearance of disease, a goal increasingly important with the advent of intraperitoneal chemotherapy and cytostatic targeted treatments [12] . CA-125 is an established biomarker in ovarian cancer. However, there are little existing data concerning CA-125 regression during NAC as a valid surrogate for outcome. Le and colleagues [13] crudely defined CA-125 response during NAC as a decrease of [50% from baseline and found no significant association between response and progression-free survival. The same authors subsequently examined CA-125 normalization during NAC as a predictor of survival. 17.8 and 57.8% of patients achieved CA-125 normalization prior to IDS and on completion of all primary chemotherapies, respectively. However, normalization of CA-125 (i.e. \35 kU/L) was not an independent predictor of OS [14] .
Tate et al. calculated CA-125 regression coefficients in a manner similar to the current study, demonstrating a correlation with survival, although analysis was limited to the univariate level. A coefficient of C-0.039 was used to stratify good and poor responders and, of the 50 patients studied, 33 (66%) were classified as responders. 3-year survival was 70.5 vs. 43.3% in responders and nonresponders, respectively [15] . Based on these criteria, twothirds of patients would be classified as responders in our study (CA-125 half-life \ 17.8 days), with equivalent 3-year survival times of 50.6 and 13.1%. The reason for our poorer outcomes is uncertain but may reflect the often high-risk/poor performance status indication for IDS in our population.
Unlike previous studies, we have gone on to demonstrate the independent predictive and prognostic value of CA-125r on multivariate analysis. When considering time to second-line chemotherapy and time to CA-125 progression, CA-125r is a strong and independent prognostic marker, even when considering the degree of cytoreduction subsequently achieved at surgery. CA-125r is also independently prognostic for OS when the degree of cytoreduction is not considered, which is a valid omission given that, prior to surgery, the degree of cytoreduction is unknown. Women with a CA-125 half-life of less than 11.8 days had median OS more than double (52.7 vs. 23.3 months) that of women with longer half-lives. The best responders in this study had half-lives approaching the natural half-life of CA-125, thought to be in the region of 5 days [16] .
In addition, our data suggest that CA-125 regression and degree of cytoreduction subsequently achieved are strongly interdependent. In other words, a high CA-125r was strongly predictive of optimal cytoreduction at IDS. The obvious drawback to determination of CA-125r is that it requires more than one marker reading and mathematical calculation. A more attractive option would be the use of an absolute pre-operative level and a CA-125 of 500 IU/ml has recently been correlated with optimal cytoreduction (ROC AUC of 0.89) [8] . However, this has not been replicated by others [9] . We also considered whether a CA-125 response based on GCIG criteria [17] (excluding 28 day confirmation) would be a more simple way of predicting surgical outcome. However, of the 60 women assessable by such criteria, all but three would have been deemed to have responded, thus negating its value. Furthermore, despite the widespread use of computed tomography (CT) and the development of predictive radiological models, the accuracy of predicting optimal surgery remains limited [18] . Combining CA-125 regression with radiological data may increase the accuracy of predicting surgical outcome.
This study clearly has limitations, primarily related to its retrospective nature. The chemotherapy regimen used and number of cycles varied. The number of CA-125 measurements available in each patient was also variable and may have been influenced by the observed response. A third of women underwent paracentesis during or shortly before NAC, the influence of which on serum CA-125 levels remains uncertain. We have also not examined those patients originally planned for IDS but who, following NAC, did not proceed to surgery, either due to excellent response to chemotherapy or lack of response/progression.
In conclusion, the current work suggests that, amongst chemotherapy responders, CA-125 regression is an important surrogate endpoint during NAC. A long CA-125 halflife predicts for suboptimal debulking and poor outcome. In such cases, consideration may be given to a more intense/ alternative chemotherapy regimen. However, such an approach remains to be tested in a prospective way.
